Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
- Conditions
- Nonneoplastic ConditionLymphoma
- Registration Number
- NCT01319526
- Lead Sponsor
- AIDS Malignancy Consortium
- Brief Summary
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV.
PURPOSE: This research study is studying biomarkers in blood samples from patients with HIV infection and stage III or stage IV Hodgkin lymphoma undergoing chemotherapy.
- Detailed Description
OBJECTIVES:
Primary
* To quantify HIV-1 persistence in prospectively collected samples from patients on suppressive antiretroviral therapy undergoing chemotherapy for Hodgkin lymphoma.
OUTLINE: This is a multicenter study.
Blood samples are collected before, during, and after treatment for lymphoma for HIV-1 RNA levels using standard and single copy assays and HIV-1 DNA quantification (peripheral blood mononuclear cells).
After completion of treatment, patients are followed up periodically for up to 2 years.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in viral load from baseline to each subsequent time point Baseline, after each cycle of treatment, restaging, treatment completion, year 1, year 2, study discontinuation Time frame for outcome measures dependent on study calendar for parent protocol, S0816, which varies by subject's PET scan status.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
🇺🇸Baltimore, Maryland, United States